a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration earlier this year ...
non-opioid alternative to current IV-based cataract surgery sedation protocols, which generally involve the administration of opioids,” said Dr Larry Dillaha, Chief Executive Officer of Melt.
Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, non-opioid sedation tablet for cataract surgery. The pivotal study's design ...